Skip to main content
    CMS.gov Centers for Medicare & Medicaid Services CMS.gov Centers for Medicare & Medicaid Services opens in new window
    CMS.gov Centers for Medicare & Medicaid Services
    Centers for Medicare & Medicaid Services

    Main header

    • About Us
    • Newsroom
    • Data & Research
    MCD
    Medicare Coverage Database
    • Advanced Search
    • Indexes
    • Reports
    • Downloads
    • National Coverage
      • National Coverage Analyses (NCAs)
        • Open NCAs
        • Closed NCAs
      • Coding Analyses for Labs (CALs)
        • Closed CALs
      • National Coverage Determinations (NCDs)
        • NCDs Listed Alphabetically
        • NCDs by Chapter/Section
        • Lab NCDs
      • Meetings & Assessments
        • MEDCAC Meetings
        • Technology Assessments
      • Medicare Coverage Documents
        • CMS Solicitation of Public Comments.
        • Compendia
        • Expedited Process to Remove National Coverage Determinations
        • Guidance Documents
        • National Benefit Category Analyses
        • Potential National Coverage Determination (NCD) Topics
    • Local Coverage
      • Local Coverage Determinations (LCDs)
        • LCDs by Contractor
        • LCDs by State
        • LCDs Listed Alphabetically
      • Articles
        • Articles by Contractor
        • Articles by State
        • Articles Listed Alphabetically
      • Contacts
        • All Contacts Listed Alphabetically
        • Contacts for Part A - Medicare Administrative Contractor (MAC - Part A)
        • Contacts for Part B - Medicare Administrative Contractor (MAC - Part B)
        • Contacts for Durable Medical Equipment Medicare Administrative Contractor (DME MAC)
        • Contacts for Home Health & Hospice (HHH)
    • National Coverage
      • What's New Report
      • Annual Report
    • Local Coverage
      • What's New Report
      • LCD Status Report
      • Proposed LCD Status Report
      • LCD Last Updated Report
      • Article Status Report
      • SAD Exclusion List Report
    0
    • Help & Resources
    • Page Help opens in new window
    • Contact Us

    MCD

    Y Y

    License Agreements

    Please review and accept the agreements in order to view Medicare Coverage documents, which may include licensed information and codes.

    LICENSE FOR USE OF PHYSICIANS’ CURRENT PROCEDURAL TERMINOLOGY, FOURTH EDITION ("CPT")


    End User Point and Click Amendment:

    CPT codes, descriptions and other data only are copyright 2020 American Medical Association. American Medical Association. All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the American Medical Association (AMA).

    You, your employees and agents are authorized to use CPT only as contained in the following authorized materials of CMS internally within your organization within the United States for the sole use by yourself, employees and agents. Use is limited to use in Medicare, Medicaid or other programs administered by the Centers for Medicare and Medicaid Services (CMS). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement.

    Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized herein must be obtained through the AMA, CPT Intellectual Property Services, AMA Plaza, 330 Wabash Ave., Suite 39300, Chicago, IL 60611-5885. Applications are available at the AMA Web site, http://www.ama-assn.org/cpt.

    Applicable FARS\DFARS Restrictions Apply to Government Use. Please click here to see all U.S. Government Rights Provisions. opens in new window

    AMA Disclaimer of Warranties and Liabilities.

    CPT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. AMA warrants that due to the nature of CPT, it does not manipulate or process dates, therefore there is no Year 2000 issue with CPT. AMA disclaims responsibility for any errors in CPT that may arise as a result of CPT being used in conjunction with any software and/or hardware system that is not Year 2000 compliant. No fee schedules, basic unit, relative values or related listings are included in CPT. The AMA does not directly or indirectly practice medicine or dispense medical services. The responsibility for the content of this file/product is with CMS and no endorsement by the AMA is intended or implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon no upon notice if you violate its terms. The AMA is a third party beneficiary to this Agreement.

    CMS Disclaimer

    The scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT should be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE CPT. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL CONTAINED ON THIS PAGE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

    Should the foregoing terms and conditions be acceptable to you, please indicate your agreement and acceptance by clicking below on the button labeled "I Accept".

    LICENSE FOR USE OF CURRENT DENTAL TERMINOLOGY (CDTTM)


    End User License Agreement:

    These materials contain Current Dental Terminology (CDTTM), copyright © 2020 American Dental Association (ADA). All rights reserved. CDT is a trademark of the ADA.

    The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. By clicking below on the button labeled "I accept", you hereby acknowledge that you have read, understood and agreed to all terms and conditions set forth in this agreement.

    If you do not agree with all terms and conditions set forth herein, click below on the button labeled "I do not accept" and exit from this computer screen.

    If you are acting on behalf of an organization, you represent that you are authorized to act on behalf of such organization and that your acceptance of the terms of this agreement creates a legally enforceable obligation of the organization. As used herein, "you" and "your" refer to you and any organization on behalf of which you are acting.

    1. Subject to the terms and conditions contained in this Agreement, you, your employees and agents are authorized to use CDT only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.

    2. Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT for resale and/or license, transferring copies of CDT to any party not bound by this agreement, creating any modified or derivative work of CDT, or making any commercial use of CDT. License to use CDT for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the American Dental Association web site, http://www.ADA.org.

    3. Applicable Federal Acquisition Regulation Clauses (FARS)/Department of Defense Federal Acquisition Regulation supplement (DFARS) Restrictions Apply to Government Use. Please click here to see all U.S. Government Rights Provisions. opens in new window

    4. Organizations who contract with CMS acknowledge that they may have a commercial CDT license with the ADA, and that use of CDT codes as permitted herein for the administration of CMS programs does not extend to any other programs or services the organization may administer and royalties dues for the use of the CDT codes are governed by their commercial license.

    5. ADA DISCLAIMER OF WARRANTIES AND LIABILITIES. CDT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CDT. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for software, including any CDT and other content contained therein, is with CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement.

      The ADA is a third party beneficiary to this Agreement.

    6. CMS DISCLAIMER. The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT should be addressed to the ADA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CDT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material covered by this license. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

      The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. If the foregoing terms and conditions are acceptable to you, please indicate your agreement by clicking below on the button labeled "I Accept". If you do not agree to the terms and conditions, you may not access or use software. Instead you must click below on the button labeled "I Do Not Accept" and exit from this computer screen.

    LICENSE FOR NATIONAL UNIFORM BILLING COMMITTEE (NUBC)


    American Hospital Association Disclaimer


    The American Hospital Association ("the AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.


    The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. If the foregoing terms and conditions are acceptable to you, please indicate your agreement by clicking below on the button labeled "I Accept". If you do not agree to the terms and conditions, you may not access or use the software. Instead, you must click below on the button labeled "I Do Not Accept" and exit from this computer screen.

    Local Coverage Determination (LCD):
    Treatment of Males with Low Testosterone (L36569)


    Alert: Codes have moved from LCDs to Articles! Learn more opens in new window

    Select the Print Complete Record, Add to Basket or Email Record Buttons to print the record, to add it to your basket or to email the record.
    Printing Note:
    To print an entire document, use the Need a PDF Button or the Print Complete Record Button.
    Note: Documents with coding fields will include all codes in each group.

    To print only the current visible page contents, use the Print Button in the page header.
    • Expand All All sections on the page are Expanded
    • Collapse All All sections on the page are Collapsed

    Expand/Collapse the Contractor Information section Contractor Information

    Contractor NameContract TypeContract NumberJurisdictionState(s)
    Noridian Healthcare Solutions, LLC A and B MAC02101 - MAC AJ - FAlaska
    Noridian Healthcare Solutions, LLC A and B MAC02102 - MAC BJ - FAlaska
    Noridian Healthcare Solutions, LLC A and B MAC02201 - MAC AJ - FIdaho
    Noridian Healthcare Solutions, LLC A and B MAC02202 - MAC BJ - FIdaho
    Noridian Healthcare Solutions, LLC A and B MAC02301 - MAC AJ - FOregon
    Noridian Healthcare Solutions, LLC A and B MAC02302 - MAC BJ - FOregon
    Noridian Healthcare Solutions, LLC A and B MAC02401 - MAC AJ - FWashington
    Noridian Healthcare Solutions, LLC A and B MAC02402 - MAC BJ - FWashington
    Noridian Healthcare Solutions, LLC A and B MAC03101 - MAC AJ - FArizona
    Noridian Healthcare Solutions, LLC A and B MAC03102 - MAC BJ - FArizona
    Noridian Healthcare Solutions, LLC A and B MAC03201 - MAC AJ - FMontana
    Noridian Healthcare Solutions, LLC A and B MAC03202 - MAC BJ - FMontana
    Noridian Healthcare Solutions, LLC A and B MAC03301 - MAC AJ - FNorth Dakota
    Noridian Healthcare Solutions, LLC A and B MAC03302 - MAC BJ - FNorth Dakota
    Noridian Healthcare Solutions, LLC A and B MAC03401 - MAC AJ - FSouth Dakota
    Noridian Healthcare Solutions, LLC A and B MAC03402 - MAC BJ - FSouth Dakota
    Noridian Healthcare Solutions, LLC A and B MAC03501 - MAC AJ - FUtah
    Noridian Healthcare Solutions, LLC A and B MAC03502 - MAC BJ - FUtah
    Noridian Healthcare Solutions, LLC A and B MAC03601 - MAC AJ - FWyoming
    Noridian Healthcare Solutions, LLC A and B MAC03602 - MAC BJ - FWyoming

    Expand/Collapse the browser section LCD Information

    Document Information

    LCD ID
    L36569

    LCD Title
    Treatment of Males with Low Testosterone

    Proposed LCD in Comment Period
    N/A

    Source Proposed LCD
    DL36569

    AMA CPT / ADA CDT / AHA NUBC Copyright Statement
    CPT codes, descriptions and other data only are copyright 2020 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

    Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

    Current Dental Terminology © 2020 American Dental Association. All rights reserved.

    Copyright © 2013 - 2020, the American Hospital Association, Chicago, Illinois. Reproduced by CMS with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816. You may also contact us at ub04@aha.org.


    Original Effective Date
    For services performed on or after 07/12/2016

    Revision Effective Date
    For services performed on or after 11/01/2019

    Revision Ending Date
    N/A

    Retirement Date
    N/A

    Notice Period Start Date
    05/27/2016

    Notice Period End Date
    07/11/2016

    CMS National Coverage Policy

    Title XVIII of the Social Security Act (SSA), §1862(a)(1)(A), states that no Medicare payment shall be made for items or services that “are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.”

    Title XVIII of the Social Security Act, §1833(e), prohibits Medicare payment for any claim lacking the necessary documentation to process the claim.

    42 Code of Federal Regulations (CFR) §410.32 Diagnostic x-ray tests, diagnostic laboratory tests, and other diagnostic tests: Conditions.

    CMS Internet Online Manual Pub. 100-02 (Medicare Benefit Policy Manual), Chapter 15, Section 80, “Requirements for Diagnostic X-Ray, Diagnostic Laboratory, and Other Diagnostic Tests”

    CMS Internet-Only Manuals, Publication 100-04, Medicare Claims Processing Manual, Chapter 16, §50.5 Jurisdiction of Laboratory Claims, 60.12 Independent Laboratory Specimen Drawing, 60.2. Travel Allowance.

    CMS Internet Online Manual Pub. 100-04 (Medicare Claims Processing Manual), Chapter 23 (Section 10) “Reporting ICD Diagnosis and Procedure Codes”.

    CMS Internet-Only Manual, Pub 100-04, Medicare Claims Processing Manual, Chapter 12, §30-Correct Coding Policy

    Coverage Guidance
    Coverage Indications, Limitations, and/or Medical Necessity

    Noridian has noted a rapid increase in the use of testosterone supplements that exceed the expected use in the Medicare population based on current published data. According to a Health Technology Assessment on Testosterone Testing from the Washington State Health Care Authority, the presence of low serum testosterone is 9.0% in men aged 45 to 54 years, 16.5% in men aged 55 to 64 years, and 18.3% in men aged 65 to 74 years. These estimates were derived from the National Health and Nutrition Examination Survey III (NHANESIII), which defined low testosterone levels as < 300 nanogram per deciliter (ng/dL) (10.4 nanomoles per liter [nmol/L]). The diagnosis of hypogonadism depends on measuring the total, free and/or biologically active testosterone; sex hormone binding globulin (SHBG) and the pituitary axis. Male hormone is bound to SHBG, and SHBG tends to rise with age, lowering the free testosterone level. Testosterone level accuracy varies among labs with different assays, and can be affected by chronic diseases, age, levels of binding, measurement variables, testing accuracy, etc. Estimates of the low end of testosterone depend on the method and accuracy of testing and can be as low as 160 ng/dl. Decisions on hypogonadism depend on both repeated hormone testing and a group of clinical symptoms. Neither alone is adequate for defining hypogonadism.

    Testosterone levels are controlled by interaction of the testicular-pituitary-hypothalamic axis. Primary hypogonadism is failure of the testes to produce testosterone (for a number of reasons) and is usually accompanied by elevated LH and/or FSH. Secondary hypogonadism is disruption of the testicular-pituitary-hypothalamic pathway and may be due to pituitary or hypothalamic axis damage including systemic illness and genetic aberration. Age related hypogonadism (e.g. lower testosterone in the older male population) is not necessarily a disease and may be asymptomatic and / or may be related or associated with many chronic illnesses. “Low T Syndrome” or “Low T” is not a syndrome and may be an incidental finding or lab error. Low serum testosterone alone does not constitute a diagnosis of androgen deficiency or clinical hypogonadism. Diagnosis of a clinical condition requires the presence of certain characteristic symptoms as well as an abnormally low serum testosterone.

    Many of the symptoms are not specific to, and not directly correlated to specific levels of testosterone. Guidelines from the Endocrine Society suggest some of the following symptoms may be related to low serum testosterone but may also have many other causes in the elderly population:

    More Specific Signs / Symptoms

      • Incomplete or delayed sexual development; eunuchoidism

     

      • Reduced sexual desire (libido) and activity

     

      • Breast discomfort, gynecomastia

     

      • Loss of body (axillary and pubic) hair, reduced shaving

     

      • Very small (Especially < mL) or shrinking testes

     

      • Inability to father children

     

      • Low or zero sperm count

     

      • Height loss, low-trauma fracture, low bone mineral density

     

      • Hot flushes, sweats


    Less Specific Signs/Symptoms

      • Decreased energy, motivation, initiative and self confidence

     

      • Feeling sad or blue, depressed mood, dysthymia

     

      • Poor concentration and memory

     

      • Sleep disturbance, increased sleepiness

     

      • Mild anemia

     

      • Reduced muscle bulk and strength

     

      • Increased fat or increased body mass index

     

      • Diminished physical or work performance


    Noridian expects that the evaluation of primary hypogonadism be undertaken with at least 2 separate serum testosterone levels taken on two different days in the morning (when testosterone secretion is highest) , and / or two morning levels of “free” or bioavailable testosterone) and LH or FSH levels. Elevated LH /FSH confirms primary hypogonadism and the potential need for replacement hormone. If the two testosterone determinations are low AND the LH/FSH levels are also low, pituitary disease (including a serum prolactin) or chronic diseases should be assessed before making a diagnosis of age related low testosterone. Only patients with low testosterone associated significant symptoms should be considered for treatment. A comprehensive examination is required to evaluate for medications or chronic diseases known to cause decreased energy, memory problems, impotence and mental health problems.

    Noridian would consider the low testosterone related symptoms from the nonspecific and specific groups described above to be documented in the chart along with two low testosterone levels drawn on two mornings and a single LH or FSH to demonstrate the need for testosterone therapy in the age related group of symptomatic androgen deficiency. Documentation of the symptoms, signs, physical examination and lab tests must be available in the chart if requested.

    Treatment of symptoms associated with low testosterone is controversial. It is not certain if low testosterone is the cause of the symptoms, a marker for underlying chronic diseases, or the effect of the symptoms-and there is a considerable placebo effect. Long term effects of testosterone on the geriatric population are mixed but are being studied by the NIH. Long term use of testosterone can damage the hypothalamic-pituitary-testicular axis and lead to permanent testicular failure.

    Testosterone replacement therapy is contraindicated in patients with breast cancer and untreated prostate cancer. There are recent FDA listed warnings about thromboembolic disease, increase in erythrocythemia, and hypertension. The clinical records shall reflect that these issues were discussed with the patient before initiating therapy. Some physicians recommend obtaining baseline PSA testing and ongoing monitoring to test for prostate cancer.

    Long term testosterone therapy will shrink testicular tissue and can lead to infertility, and therefore would be contraindicated in those interested in reproduction.

    Where replacement is indicated, the dose of replacement therapy should be the least amount necessary to obtain a serum testosterone in the low normal range. Testosterone replacement can be administered by many routes. The current preferred routes are by transdermal preparations. Since topical or transdermal agents are administered daily in low dose, the risk of supraphysiological or subtherapeutic levels is minimized. The use of topical agents is thought to minimize adverse events. Indeed, in series examining the toxicity of topical agents, adverse events are nearly nonexistent when administered by these routes (Steidle et al., 2003). The main disadvantage of the topical agents are their high cost ($100 to $150 per month), substantially higher than self-administered injection therapy, and the potential risk of inadvertent transfer of hormone to women or children through skin contact. There is no evidence that unusually high doses-or higher than published frequencies of administration-are any more effective than doses established by the FDA and could lead to increased side effects. Ongoing monitoring of hormone levels and side effects are necessary.



    Summary of Evidence

    N/A



    Analysis of Evidence
    (Rationale for Determination)


    N/A



    Expand/Collapse the General Information section General Information

    Associated Information

    N/A

    Sources of Information

    1. Bhasin, MD, S., Travison, PHD, T., & Jasuja, PhD, R. Testosterone and Aging. Translational Endocrinology & Metabolism, 2 (2), 39-72. 2011.

    2. Bhasin, MD, S., Cunningham, G., & Hayes, F. (2013). Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline. JCEM

    3. Brannigan, MD, R., Paduch, MD, PHD, D., & Fuchs, E., et al; The Laboratory Diagnosis of Testosterone Deficiency, 2013 AUA White Paper., (American Urological Association Education and Research, Inc.).

    4. FDA Safety Alert: Testosterone Products: Drug Safety Communication - FDA Cautions About Using Testosterone Products for Low Testosterone Due to Aging; Requires Labeling Change to Inform of Possible Increased Risk of Heart Attack and Stroke; UPDATE 04/15/2015.

    5. Handelsman, MBBS, PHD, D., & Perls MD, MPH, T. (n.d.). , Disease Mongering of Age-Associated Declines in Testosterone and Growth Hormone Levels. Journal of the American Geriatrics Society, 63(4), 809-811. April 2015.

    6. Huhtaniemi, I. (2014). Late-onset hypogonadism: Current concepts and controversies of pathogenesis, diagnosis and treatment. Asian Journal of Andrology, 16(2), 192-202.

    7. Paduch, D. et al "Testosterone Replacement in Androgen-Deficient Men With Ejaculatory Dysfunction: A Randomized Controlled Trial" J Clin Endicrinol Metab. 2014-4434. 2015.

    8. Rishi Sharma, Olurinde A. Oni, Kamal Gupta, et.al. European Heart Journal, published online: 6 August 2015.

    9. Steidle, C.P. MD, New Advances in the Treatment of Hypogonadism in the Aging Male, Rev Urol. 2003; 5 (Suppl 1): S34–S40.

    10. Testosterone Testing, Health Technology Assessment Program (HTA) Washington State Health Care Authority (Draft Report) February 6, 2015.

    Bibliography

    N/A

    Expand/Collapse the Revision History section Revision History Information

    Revision History DateRevision History NumberRevision History ExplanationReason(s) for Change
    11/01/2019 R5

    The LCD is revised to remove CPT/HCPCS codes in the Keyword Section of the LCD.

    At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

    • Other (The LCD is revised to remove CPT/HCPCS codes in the Keyword Section of the LCD.
      )
    11/01/2019 R4

    11/01/2019: At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage.

    As required by CR 10901, all billing and coding information has been moved to the companion article, this article is linked to the LCD.

    • Provider Education/Guidance
    • Revisions Due To Code Removal
    10/01/2017 R3

    08/21/2017: At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice.  This revision is not a restriction to the coverage determination; and, therefore not all the fields included on the LCD are applicable as noted in this policy.

    LCD is revised to add the following diagnoses effective 10/01/2017:

    D44.3: Neoplasm of uncertain behavior of pituitary gland

    • Revisions Due To ICD-10-CM Code Changes
    01/01/2017 R2 2017 CPT Coding update to include 84410
    • Revisions Due To CPT/HCPCS Code Changes
    10/01/2016 R1 Added ICD-10 CM Code N50.89 per ICD-10 CM 2016-2017 Coding Updates.
    • Revisions Due To ICD-10-CM Code Changes

    Expand/Collapse the Associated Documents section Associated Documents

    Attachments
    N/A
    Related Local Coverage Documents
    Article(s)
    A55057 - Billing and Coding: Testopel Coverage opens in new window
    A57616 - Billing and Coding: Treatment of Males with Low Testosterone opens in new window
    A55055 - Response to Comments: Treatment of Males with Low Testosterone opens in new window
    Related National Coverage Documents
    N/A
    Public Version(s)
    Updated on 01/29/2020 with effective dates 11/01/2019 - N/A
    Updated on 10/24/2019 with effective dates 11/01/2019 - N/A
    Some older versions have been archived. Please visit the MCD Archive Site to retrieve them.

    Expand/Collapse the Keywords section Keywords

    N/A
    Read the LCD Disclaimer opens in new window
    Footer Links
    • Submit Feedback/Ask a Question
    30

    Get email updates

    Sign up to get the latest information about your choice of CMS topics in your inbox. Also, you can decide how often you want to get updates.

    CMS & HHS WEBSITES

    • Medicare.govopens in new window
    • MyMedicare.govopens in new window
    • Medicaid.govopens in new window
    • InsureKidsNow.govopens in new window
    • HealthCare.govopens in new window
    • HHS.govopens in new window

    HELPFUL LINKS

    • Acronyms
    • Archive
    • Contacts
    • Glossary
    • Privacy policy

    RSS FEEDS

    • Newsroom
    • Blog
    • Podcast
    U.S. Department of Health & Human Servicesopens in new window Centers for Medicare & Medicaid Servicesopens in new window

    A federal government website managed and paid for by the U.S. Centers for Medicare & Medicaid Services.

    7500 Security Boulevard, Baltimore, MD 21244

    opens in new window opens in new window opens in new window

    TOOLS

    • Web policiesopens in new window
    • Plain languageopens in new window
    • No Fear Actopens in new window
    • Freedom of Information Actopens in new window
    • Inspector Generalopens in new window